Targeting a novel surface antigen, ryk, with the antibody-drug conjugate, slv-404, is effective in richter transformation patient-derived xenografts
Matilde Micillo(Department of Medical Sciences), Silvia Deaglio(Department of Medical Sciences), Tiziana Vaisitti(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Katti Jessen(Intel (United States)), Brian J. Lannutti(Fate Therapeutics (United States)), Victor Navarro‐Tableros(CSI Piemonte), Maria Chiara Montalbano(University of Turin), Samir Mouhssine(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Giulia Omezzolli(Department of Medical Sciences), Francesco Edoardo Vallone(Department of Medical Sciences), Amelia Fascì(Department of Medical Sciences), Beatrice Pirajno(Department of Medical Sciences), Elisabetta Bolli(Department of Public Health), Nahal Nabelsi(Department of Medical Sciences), Candida Vitale(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Cited by 0
Related Papers
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
|The Journal of Experimental Medicine|2007|2.4k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The translational landscape of mTOR signalling steers cancer initiation and metastasis
|Nature|2012|1.4k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890